UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Semaglutide
DrugAlso known as: compounded semaglutide, oral Wegovy, Semaglyn, SEMAGLYN, SEMAGLYN™
Drug Profile
Semaglutide is a GLP-1 analogue marketed as OZEMPIC for type 2 diabetes and cardiovascular risk reduction in adults with established cardiovascular disease. It acts as a GLP-1 receptor agonist with glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, and minor delay of gastric emptying. U.S. initial approval in this label is 2017.
- Drug Class
- Glucagon-like peptide-1 (GLP-1) receptor agonist
- Approval Status
- FDA approved (Initial U.S. Approval: 2017)
- Mechanism of Action
- GLP-1 receptor agonist that stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner, with minor delay in early postprandial gastric emptying.
- OZEMPIC
- \Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus\
- \Reduce risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease\
Related News
Oral Semaglutide Cuts Heavy Drinking; VA Launches Alcoholism Trial
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
TMates Weightloss Semaglutide: Compounded Semaglutide Telehealth Program Explained
TMates Weightloss Semaglutide is a compounded semaglutide telehealth program dispensed by U.S. pharmacies. It offers tailored dosing, a 30-day money-back guarantee, and support for appetite control and weight maintenance.
Clinics Offer Semaglutide and Tirzepatide Weight Loss Programs
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Lupin Posts Record Q3 FY2026 Results, Prepares Generic Semaglutide Launch
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
How Much BAC Water to Add to 3mg Semaglutide: Concentration Guide
Adding bacteriostatic water to a 3mg semaglutide vial changes its concentration; the correct amount depends on the pharmacy's specification. FDA-approved semaglutide pens should not be reconstituted. The FDA has received reports of hospitalizations linked to compounded semaglutide dosing errors.
Orforglipron Beats Oral Semaglutide in Type 2 Diabetes Trial; Hair Loss on GLP-1s Addressed
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Padgett Medical Center Offers Compounded Semaglutide Starting at $149/Month in Plant City, FL
Padgett Medical Center offers doctor-supervised compounded semaglutide starting at $149/month for Plant City, FL, with telehealth and statewide shipping. The medication is not FDA-approved.
Patent Cliff: Blockbuster Drugs Worth Up to $500B Face Generic Competition
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Semaglutide Linked to Lower Seizure and Alcohol-Related Hospitalization Risks; Brazil Approves Five New GLP-1 Drugs
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770841 |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
RECRUITING | PHASE3 |
| NCT07769047 |
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors |
NOT_YET_RECRUITING | PHASE4 |
| NCT07767175 |
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07743983 |
A Study of BGM0504 in Early T2DM With Obesity |
RECRUITING | PHASE3 |
| NCT07732426 |
Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies |
RECRUITING | NA |
| NCT07701005 |
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity |
COMPLETED | |
| NCT07668414 |
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide |
NOT_YET_RECRUITING | PHASE3 |
| NCT07668388 |
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes |
RECRUITING | PHASE2 |
| NCT07662213 |
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus |
RECRUITING | PHASE3 |
| NCT07639021 |
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity |
RECRUITING | PHASE2 |